Related Experiment Video

Updated: May 8, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

[The natural course of chronic HBV+HCV infection in children]

T V Strokova, I V Machulan, T B Sentsova

    Eksperimental'Naia I Klinicheskaia Gastroenterologiia = Experimental & Clinical Gastroenterology
    |August 20, 2013
    PubMed

    Insights

    Chronic viral hepatitis (CVH) is increasing in children. Mixed hepatitis B+C in children leads to faster disease progression and cirrhosis, requiring long-term monitoring.

    Area of Science:

    • Pediatric Gastroenterology and Hepatology
    • Virology
    • Immunology

    Context:

    • Increasing prevalence of chronic viral hepatitis (CVH) in pediatric populations.
    • Mixed hepatitis B+C (CH B+C) presents a significant clinical challenge.
    • Association of mixed hepatitis with accelerated disease progression and liver cirrhosis.

    Purpose:

    • To present long-term monitoring data for children diagnosed with chronic hepatitis B+C (CH B+C).
    • To elucidate the specific clinical manifestations of CH B+C in pediatric patients.
    • To analyze biochemical, immunological, and morphological changes in the natural history of CH B+C.

    Summary:

    • This study monitored children with chronic hepatitis B+C (CH B+C) over an extended period.
    • Key clinical, biochemical, immunological, and morphological features were documented.
    • Findings highlight the aggressive nature of mixed hepatitis B+C in children, often leading to cirrhosis.

    Impact:

    • Provides crucial insights into the natural history of pediatric CH B+C.
    • Informs clinical management strategies for children with chronic viral hepatitis.
    • Contributes to understanding disease progression and potential interventions for liver cirrhosis in children.

    More Related Videos

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection11:14

    Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

    Published on: November 7, 2018

    Related Concept Videos

    Hepatitis01:25

    Hepatitis

    Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
    Viral Hepatitis I: Introduction01:28

    Viral Hepatitis I: Introduction

    Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
    Cytomegalovirus Disease01:27

    Cytomegalovirus Disease

    Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...